A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)

Trial Profile

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Glembatumumab vedotin (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms METRIC
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 23 Aug 2017 According to a Celldex Therapeutics Inc media release, the study calls for 203 progression events for evaluation of the primary endpoint, which will be assessed based on an independent, central reading of patient scans. The sum of the data, including the secondary endpoints of response rate, overall survival, duration of response and safety, will be important in assessing clinical benefit.
    • 23 Aug 2017 According to a Celldex Therapeutics Inc media release, the company expects to report top-line data by the second quarter of 2018, but it could occur earlier or later based on the rate of events in the study.
    • 23 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to a Celldex Therapeutics Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top